Abstract
Tumor necrosis factor (TNF) is a central pro-inflammatory cytokine that regulates the expression of numerous signaling pathways implicated in the progression of the immunological reaction. Unraveling the importance of TNF on the pathogenesis of inflammatory bowel disease (IBD) promoted anti-TNF antibodies as novel therapeutic agents. Initially, the main hypothesis behind the clinical application of anti-TNF antagonists in the clinic was that they exert their effects solely through neutralization of TNF. Anti-TNF antibodies induce and maintain clinical remission in patients with minimal side-effects. However, the cellular and molecular mechanisms of actions of the anti-TNF antibodies remain unknown. Various mechanisms of action have been proposed such as activation of transmembrane TNF mediated reverse signaling, induction of apoptosis, pro-inflammatory cytokine down-regulation, complement dependent cytotoxicity, antibodydependent cell-mediated cytotoxicity, and finally activation of regulatory immune cells via interactions with the Fc receptors. The observed discrepancies in the clinical efficacies as well as the differences in the structure of the various TNF antagonists nourish the investigation for additional modes of function.
Keywords: Antibody-dependent cell-mediated cytotoxicity, complement dependent cytotoxicity, Crohn’s disease, inflammatory bowel disease, macrophages, reverse signaling, tumor necrosis factor, ulcerative colitis.
Current Drug Targets
Title:Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Volume: 14 Issue: 12
Author(s): Angelos Oikonomopoulos, Welmoed K. van Deen and Daniel W. Hommes
Affiliation:
Keywords: Antibody-dependent cell-mediated cytotoxicity, complement dependent cytotoxicity, Crohn’s disease, inflammatory bowel disease, macrophages, reverse signaling, tumor necrosis factor, ulcerative colitis.
Abstract: Tumor necrosis factor (TNF) is a central pro-inflammatory cytokine that regulates the expression of numerous signaling pathways implicated in the progression of the immunological reaction. Unraveling the importance of TNF on the pathogenesis of inflammatory bowel disease (IBD) promoted anti-TNF antibodies as novel therapeutic agents. Initially, the main hypothesis behind the clinical application of anti-TNF antagonists in the clinic was that they exert their effects solely through neutralization of TNF. Anti-TNF antibodies induce and maintain clinical remission in patients with minimal side-effects. However, the cellular and molecular mechanisms of actions of the anti-TNF antibodies remain unknown. Various mechanisms of action have been proposed such as activation of transmembrane TNF mediated reverse signaling, induction of apoptosis, pro-inflammatory cytokine down-regulation, complement dependent cytotoxicity, antibodydependent cell-mediated cytotoxicity, and finally activation of regulatory immune cells via interactions with the Fc receptors. The observed discrepancies in the clinical efficacies as well as the differences in the structure of the various TNF antagonists nourish the investigation for additional modes of function.
Export Options
About this article
Cite this article as:
Oikonomopoulos Angelos, van Deen K. Welmoed and Hommes W. Daniel, Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990164
DOI https://dx.doi.org/10.2174/13894501113149990164 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insulin and Endothelial Function: Physiological Environment Defines Effect on Atherosclerotic Risk
Current Diabetes Reviews Role of Salt and Potassium in Hypertension and the Associated Organ Damages
Current Hypertension Reviews Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Buckwheat: A Useful Food and Its Effects on Human Health
Current Nutrition & Food Science Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Blood Pressure as a Therapeutic Target in Stroke
Current Topics in Medicinal Chemistry Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures
Current Molecular Medicine Gender Differences in Autonomic Control of the Cardiovascular System
Current Pharmaceutical Design Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer
Current Clinical Pharmacology Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Non-ambient Conditions in the Investigation and Manufacturing of Drug Forms
Current Pharmaceutical Design